Understand the source comparison
Peptides for Neck Pain Protocol — Research vs Clinical Comparison
BPC-157 Angiogenesis stimulation, nitric oxide stabilization 250–500 mcg daily Preclinical animal models, no RCTs Subcutaneous injection Strong mechanistic rationale; human efficacy data limited to case reports TB-500 Actin polymerization, cell migration 2 mg
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Angiogenesis stimulation, nitric oxide stabilization
- 250–500 mcg daily
- Preclinical animal models, no RCTs
- Subcutaneous injection
- Strong mechanistic rationale; human efficacy data limited to case reports
- TB-500
- Actin polymerization, cell migration
- 2 mg twice weekly (loading), 2 mg weekly (maintenance)
- Phase I safety trials; efficacy data anecdotal
- Well-tolerated in humans; extrapolated from thymosin Beta-4 wound healing research
- Thymalin
- Immune modulation, thymic peptide activity
- 5–10 mg 2–3 times weekly
- Limited human trials; primarily Eastern European research
- Intramuscular or subcutaneous
- Niche application for autoimmune-mediated neck inflammation
- NSAIDs (Comparison)
- COX enzyme inhibition
- Varies by drug (ibuprofen 400–800 mg TID)
- Extensive RCT evidence
- Oral
- Gold standard for symptom relief; no tissue repair mechanism
- Corticosteroid Injection
- Broad anti-inflammatory suppression
- 40–80 mg methylprednisolone (single dose)
- RCT-supported for radiculopathy
- Epidural or trigger point
- Fast symptom relief; risk of tissue weakening with repeat use
- BPC-157 and TB-500 occupy a different therapeutic category than pharmaceuticals. They're research compounds with compelling preclinical data but incomplete human trial evidence. The comparison to NSAIDs isn't apples-to-apples: one suppresses symptoms, the other targets tissue-level repair pathways.